Ethanol extract of Dendrobium chrysotoxum Lindl ameliorates diabetic retinopathy and its mechanism.

Diabetic retinopathy (DR) is the most common and serious complication of diabetes mellitus (DM). The present study investigates the amelioration of ethanol extract of Dendrobium chrysotoxum Lindl (DC) on streptozotocin (STZ)-induced DR and its engaged mechanism. Retinal immunofluorescence staining with cluster of differentiation 31 (CD31) demonstrated that DC (30-300 mg/kg) decreased the increased retinal vessels in STZ-induced diabetic rats. Retinal histopathological observation also showed that retinal vessels were decreased in DC-treated diabetic rats. DC decreased the increased retinal mRNA expression of vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) in diabetic rats, and DC also decreased the elevated serum VEGF level. Immunohistochemical staining further evidenced that DC decreased VEGF and VEGFR2 expression in retinas. Retinal mRNA expression of matrix metalloproteinase (MMP) 2/9 was decreased in DC (300 mg/kg)-treated diabetic rats. Serum levels of MMP 2/9, basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF) A/B, insulin-like growth factor 1 (IGF-1), interleukin 1β (IL-1β), and IL-6 were all decreased in DC-treated diabetic rats. In addition, DC decreased the increased phosphorylation of p65 and the increased expression of intercellular adhesion molecule-1 (ICAM-1). In conclusion, DC can alleviate retinal angiogenesis during the process of DR via inhibiting the expression of VEGF/VEGFR2, and some other pro-angiogenic factors such as MMP 2/9, PDGF A/B, bFGF, IGF-1. In addition, DC can also ameliorate retinal inflammation via inhibiting NFκB signaling pathway.

[1]  Li Yang,et al.  Simultaneous determination of phenols (bibenzyl, phenanthrene, and fluorenone) in Dendrobium species by high-performance liquid chromatography with diode array detection. , 2006, Journal of chromatography. A.

[2]  Yi-Bo Luo,et al.  Comparison of hypoglycemic and antioxidative effects of polysaccharides from four different Dendrobium species. , 2014, International journal of biological macromolecules.

[3]  S. Oliver,et al.  Diabetic retinopathy: An update on treatment. , 2010, The American journal of medicine.

[4]  R. Simó,et al.  Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. , 2006, Current diabetes reviews.

[5]  R. Kowluru,et al.  Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9 , 2012, Expert opinion on investigational drugs.

[6]  A. Sadaka,et al.  Diabetic papillopathy: current and new treatment options. , 2011, Current diabetes reviews.

[7]  I. Herman,et al.  Vascular Complications and Diabetes: Current Therapies and Future Challenges , 2012, Journal of ophthalmology.

[8]  Mirjana Huic,et al.  Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review , 2011, British Journal of Ophthalmology.

[9]  K. Kankova,et al.  Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy , 2008, Molecular vision.

[10]  M. Stewart Critical appraisal of ranibizumab in the treatment of diabetic macular edema , 2013, Clinical ophthalmology.

[11]  Yao Tong,et al.  Review of research on Dendrobium, a prized folk medicine , 2012, Applied Microbiology and Biotechnology.

[12]  M. Kenney,et al.  Diabetic Retinopathy and VEGF , 2013, The open ophthalmology journal.

[13]  A. Thanos,et al.  Therapeutic Interventions against Inflammatory and Angiogenic Mediators in Proliferative Diabetic Retinopathy , 2012, Mediators of inflammation.

[14]  M. M. Siddiquei,et al.  Role of matrix metalloproteinase-2 and -9 in the development of diabetic retinopathy , 2012, Journal of ocular biology, diseases, and informatics.

[15]  S. Aly,et al.  The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy. , 2013, International journal of clinical and experimental medicine.

[16]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[17]  Emil Ginter,et al.  Global prevalence and future of diabetes mellitus. , 2012, Advances in experimental medicine and biology.

[18]  G. Karakiulakis,et al.  Angiogenic growth factors and their inhibitors in diabetic retinopathy. , 2010, Current diabetes reviews.

[19]  F. Bandello,et al.  The Role of Angiogenesis in the Development of Proliferative Diabetic Retinopathy: Impact of Intravitreal Anti-VEGF Treatment , 2012, Experimental diabetes research.

[20]  A. Schachat,et al.  A review of clinical trials of anti-VEGF agents for diabetic retinopathy , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[21]  Lili Ji,et al.  Streptozotocin induced diabetic retinopathy in rat and the expression of vascular endothelial growth factor and its receptor. , 2013, International journal of ophthalmology.

[22]  V. Jeganathan Anti-angiogenesis drugs in diabetic retinopathy. , 2011, Current Pharmaceutical Biotechnology.

[23]  Jeong-Chae Lee,et al.  Antioxidant and anti-hyperglycemic activity of polysaccharide isolated from Dendrobium chrysotoxum Lindl. , 2007, Journal of biochemistry and molecular biology.

[24]  L. Bhatt,et al.  Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats. , 2010, American journal of translational research.

[25]  P. Titchenell,et al.  Using the Past to Inform the Future: Anti-VEGF Therapy as a Road Map to Develop Novel Therapies for Diabetic Retinopathy , 2013, Diabetes.

[26]  David Baltimore,et al.  NF-κB: Ten Years After , 1996, Cell.

[27]  A. C. Lo,et al.  Animal Models of Diabetic Retinopathy: Summary and Comparison , 2013, Journal of diabetes research.

[28]  R. Goś,et al.  Intraocular matrix metalloproteinase 2 and 9 in patients with diabetes mellitus with and without diabetic retinopathy , 2010, Archives of medical science : AMS.

[29]  A. Finnegan,et al.  Regulation of intercellular adhesion molecule‐1 (CD54) gene expression , 1999, Journal of leukocyte biology.

[30]  R. Saxena,et al.  Current trends in the pharmacotherapy of diabetic retinopathy. , 2012, Journal of postgraduate medicine.